Table 1.

Characteristics of HIV-infected and Control Subjects

		Males			Females
		HIV+	Control	P-value§	HIV+	Control	P-value§
n*		798	150		333	131
Age (y)	Median (IQR)	43.0 (38.0–49.0)	40.0 (37.0–43.0)	<.0001	41.0 (35.0–47.0)	42.0 (37.0–44.0)	0.76
Race	Caucasian	55%	53%	0.034	33%	50%	0.014
	African American	33%	47%		55%	50%
	Other	12%	0		12%	0
Height (cm)	Median (IQR)	175 (171–180)	179 (175–183)	<.0001	163 (158–167)	165 (161–171)	0.001
Weight (kg)	Median (IQR)	75 (68–83)	85 (77–98)	<.0001	70 (59–82)	75 (64–89)	0.007
BMI (kg/m2)	Median (IQR)	24 (22–27)	27 (25–30)	<.0001	26 (22–31)	28 (23–33)	0.15
VAT (L)**	Median (IQR)	1.8 (0.8–3.0)	2.0 (1.1–3.0)	0.084	1.4 (0.6–2.4)	1.1 (0.4–1.9)	0.009
Total SAT (L)**	Median (IQR)	10.1 (7.1–14.2)	14.7 (11.1–18.8)	<.0001	25.5 (16.4–36.2)	30.1 (19.6–39.5)	0.032
CRP (mg/L)	Median (IQR)	1.69 (0.75–3.91)	0.88 (0.48–2.00)	<.0001	1.94 (0.81–4.70)	1.75 (0.60–4.37)	0.22
HCVRNA+		20%	3%	<.0001	25%	1%	<.0001
Current CD4 (cells/uL) §	Median (IQR)	345 (219–523)		0.57	359 (196–561)
HIV RNA (1000/mL) §	Median (IQR)	0.4 (0.4–10.8)		0.11	0.5 (0.4–15.2)
Current ARV Use§:	Ritonavir	30%		0.15	26%
	Indinavir	17%		0.073	13%
	Efavirenz	27%		0.001	18%
	Nevirapine	11%		0.007	18%
	Nelfinavir	17%		0.72	16%
	Kaletra	13%		0.85	13%
	Saquinavir	10%		0.052	6%
	Amprenavir	6%		0.11	4%
	Delavirdine	1%		0.77	1%
Ritonavir by dose***	High dose	12%		0.25	9%
	Low dose	18%			16%
	None	70%			75%

^*n’s are for datasets that are not age-restricted and do not exclude those with a recent opportunistic infection.

^**height-normalized,

^***high dose ritonavir ≥400mg twice daily,

^§p-values for HIV-related factors compare HIV-infected men and women.